Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL18600592 | 0.91 | ALDH1A1 (0.48) | LMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL585803 | 0.90 | LMNA (0.46) | LMNATP53SMN1; SMN2SIGMAR1L3MBTL1 | |
| SCHEMBL2918641 | 0.87 | IDO1 (0.48) | LMNASIGMAR1KCNH2SLC6A2SLC6A4 | |
| Dimethylformamide SCHEMBL133144 | 0.86 | ATM (0.41) | LMNASMN1; SMN2SIGMAR1L3MBTL1ALDH1A1 | |
| SCHEMBL28606866 | 0.85 | LMNA (0.50) | LMNATP53MAOASIGMAR1L3MBTL1 | |
| Sorbitol SCHEMBL8825016 | 0.85 | TRPA1 (0.40) | LMNASMN1; SMN2MAOAMAOBL3MBTL1 | |
| Dihydrocinnamaldehyde SCHEMBL598211 | 0.84 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2L3MBTL1ALDH1A1HPGD | |
| Biphenyl SCHEMBL3862996 | 0.82 | LMNA (0.57) | LMNASMN1; SMN2SIGMAR1L3MBTL1ALDH1A1 | |
| SCHEMBL901257 | 0.80 | LMNA (0.44) | LMNAMAOASIGMAR1KCNH2TAAR1 | |
| Phenylacetaldehyde SCHEMBL452558 | 0.80 | LMNA (0.44) | LMNATP53SMN1; SMN2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546235-B1 | WATER-SOLUBLE POLYMER ALKANALS | NEKTAR THERAPEUTICS (US) | 2021-10-20 | — | — | EP | claimed |
| JP-4764630-B2 | — | — | 2011-09-07 | — | — | JP | claimed |
| CN-1329427-C | Water soluble polymer alkanals | NEKTAR THERAPEUTICS CORP (US) | 2007-08-01 | — | — | CN | claimed |
| US-7157546-B2 | Polyoxyethylene glycol; purity, storage stability | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-01-02 | — | — | US | claimed |
| US-20060194940-A1 | 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-08-31 | — | — | US | claimed |
| JP-2005538224-A | — | — | 2005-12-15 | — | — | JP | claimed |
| CN-1688631-A | Water soluble polymer alkanals | NEKTAR THERAPEUTICS AL CORP (US) | 2005-10-26 | — | — | CN | claimed |
| EP-1546235-A2 | WATER-SOLUBLE POLYMER ALKANALS | Nektar Therapeutics Al, Corporation (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040116649-A1 | Polyoxyethylene glycol; purity, storage stability | NEKTAR THERAPEUTICS | 2004-06-17 | — | — | US | claimed |
| WO-2004022630-A2 | WATER-SOLUBLE POLYMER ALKANALS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| US-20040039056-A1 | Treatment of cell-mediated immune diseases | GLAXO GROUP LIMITED (GB) | 2004-02-26 | — | — | US | claimed |
| CN-1268886-A | Methods of treating cell-mediated immune disorders | HOFFMANN LA ROCHE (CH) | 2000-10-04 | — | — | CN | claimed |
| EP-1007020-A1 | TREATMENT OF CELL-MEDIATED IMMUNE DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-14 | — | — | EP | claimed |
| EP-0908179-A1 | Treatment of cell-mediated immune diseases | Bollag, Werner (CH) | 1999-04-14 | — | — | EP | claimed |
| WO-1999009969-A1 | TREATMENT OF CELL-MEDIATED IMMUNE DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | claimed |
| US-20240212788-A1 | HUMAN THERAPEUTIC TARGETS AND MODULATORS THEREOF | LIFEMINE THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240180844-A1 | PARTICLE COMPOSITIONS COMPRISING POLYSARCOSINE LIPID CONJUGATES | CALUSA BIO, LLC (US) | 2024-06-06 | — | — | US | disclosed |
| US-4657926-A | Behavior modifying compounds | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-04-14 | — | — | US | disclosed |
| EP-0175074-A2 | Method for producing dibenzyl monosorbitol acetal gels at lower temperature | AMERICAN CYANAMID COMPANY (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4076737-A | ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180844-A1 | PARTICLE COMPOSITIONS COMPRISING POLYSARCOSINE LIPID CONJUGATES | PHOSPHO1, SGMS1, SGMS2 | LMNA 1067/4885TP53 843/4885SMN1; SMN2 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.